Leveraging FDA's Accelerated Pathways For Market Advantage

August 23, 2017

Over the past 15 years, the FDA and Congress developed several accelerated pathways to provide incentives for manufacturers to develop innovative new drugs to treat conditions with substantial unmet need. Companies developing new drugs may be able to accelerate time to market and achieve first-mover advantage through a carefully-crafted strategy of prioritizing indications with greater potential to leverage accelerated pathways. In this whitepaper, we outline recent trends, market advantages and future considerations for these pathways, particularly in oncology.

Previous Flipbook
Faster Is The New Normal In Oncology Drug Development
Faster Is The New Normal In Oncology Drug Development

Learn five risk-mitigation strategies to produce data-rich trials, better teamwork and more regulatory inte...

Next Flipbook
Closing The Communication Gap Between Developers and the FDA
Closing The Communication Gap Between Developers and the FDA

To get the most out of pre-submission meetings and avoid misunderstandings follow this new framework.